Medtronic plc — Director's Dealing 2019

Jun 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Medtronic plc (MDT)
CIK: 0001613103
Period of Report: 2019-06-12

Reporting Person: HAKAMI HOOMAN (EVP & Group President Diabetes)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-12	Ordinary Shares	M	31731	$78.00	Acquired	95337	Direct
2019-06-12	Ordinary Shares	S	31731	$97.49	Disposed	63606	Direct
2019-06-12	Ordinary Shares	S	20933	$97.49	Disposed	42673	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-12	Stock Option (Right to Buy)	$78.00	M	31731	Disposed	2025-08-03	Ordinary Shares (31731)	Direct

Footnotes

F1: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.22 to $97.96, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $97.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: This balance increased by 959 shares due to exempt transactions such as dividend reinvestment and Employee Stock Purchase Plan.

F5: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant.